More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond, and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize recent advances on the role of CD4 + T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.
Introduction
Atherosclerosis was initially considered a disease exclusively caused by cholesterol deposition in the arterial wall. Significant evidence demonstrated that atherosclerotic plaques are not passive collections of lipids, but sites of active interactions between cells of the immune system and vascular cells that influence the fate of atheromas. 1 As evidenced in several studies in animal models and patients, both innate and adaptive immune cells participate in this process and have significant effects on the initiation and progression of atherosclerotic lesions. 2, 3 Interactions between immune and vascular cells trigger a self-perpetuating inflammatory cycle that generates a chronic inflammatory milieu that promotes atherosclerotic plaque growth and rupture. 1 The hypothesis that inflammation is a significant driving factor in atherosclerosis is now the focus of phase III clinical trials that test strategies to reduce inflammatory mediators. 4 On-going phase III trials target the innate inflammatory cytokines interleukin-1b (IL-1b; targeted with Canakinumab, a human monoclonal anti-IL-1b antibody in the CANTOS trial), IL-6, and tumour necrosis factor-a (TNF-a; targeted with low-dose methotrexate in the CIRT trial). The immune response in atherosclerosis is multifaceted and, in addition to innate cells, adaptive immune responses have significant contributions. Indeed, adaptive immune cells such as T lymphocytes, B lymphocytes, and antibodies have been identified in atherosclerotic plaques and circulation of patients with atherosclerosis. 5 Moreover, substantial evidence from animal studies clearly demonstrates that specialized subsets of T and B lymphocytes exert either protective or promoting effects on atherogenesis. 2 These data suggest that more targeted approaches may be required to successfully retune the immune system and modulate the complex inflammatory response in atherosclerosis. In the following sections, we will summarize recent advances on the role of CD4 + T lymphocytes in atherosclerosis, focusing on two subsets [CD4 + CD28 null and regulatory T (Treg) cells] that are at opposing poles of the inflammatory process that underlies atherosclerosis and harbour therapeutic potential.
CD4

T cells in atherosclerosis
T lymphocytes represent the second largest immune cell population in atherosclerotic plaques after macrophages. Both helper (CD4 + ) and cytotoxic (CD8 + ) T cells have been identified in atheromas.
However, the inflammatory response in atherosclerosis is dominated by Th1 lymphocytes, the most abundant T-cell subset in plaques. Characteristically, Th1 cells are identified by the production of interferon-g (IFN-g), a cytokine that promotes atherosclerosis and plaque rupture through effects on several cells in atherosclerotic lesions. 1 12 We found that, in ACS, OX40 and 4-1BB regulate not only the cytokine production, but also the release of perforin from CD28 null T cells. 10 Another distinguishing feature from conventional CD28 + T lymphocytes is the reduced sensitivity of CD28 null T cells to apoptosis induction. In rheumatoid arthritis (RA), this has been attributed to an increase Figure 1 Overview of cardinal features and potential strategies to target CD28 null and regulatory T-cell lymphocytes in atherosclerosis.
CD28
null T cells expand in the circulation and atherosclerotic plaques in patients with acute coronary syndrome. These cells produce high levels of inflammatory cytokines (interferon-g and tumour necrosis factor-a) and express and release cytotoxic molecules (perforin and granzyme B). The production of cytokines and cytotoxic molecules is modulated by co-stimulatory receptors OX40 and 4-1BB, which are up-regulated on CD28 null T cells. Moreover, CD28 null T cells are resistant to apoptosis due to reduction in apoptotic molecules Fas, Bim, and Bax, which underlies the expansion of this cell subset in acute coronary syndrome patients. Several strategies have been proposed to reduce the number and/or function of CD28 null T cells such as tumour necrosis factor-a inhibition, statins, sensitization to apoptosis, and inhibition of co-stimulation (CTLA4-Ig, anti-OX40, and anti-4-1BB antibodies). Regulatory T cells have crucial roles in counteracting the actions of inflammatory T lymphocytes such as CD28 null T cells. Redundant mechanisms enable regulatory T cells to suppress inflammation and T-cell actions among which are the production of anti-inflammatory cytokines (interleukin-10 and transforming growth factor-b), CTLA-4-mediated suppression, and interference with metabolic pathways (conversion of ATP into adenosine, which has anti-inflammatory properties). On-going experimental and clinical work is testing various strategies to boost the number and/or the function of circulating or intraplaque regulatory T cells such as adoptive transfer of regulatory T cells expanded in vitro, vaccination protocols that induce expansion of naturally occurring regulatory T cells or conversion of conventional CD4 + T cells into regulatory T cells, and blockade of inflammatory cytokines (tumour necrosis factor-a and interleukin-6).
Targeting T cells to treat atherosclerosis in anti-apoptotic proteins (e.g. Bcl-2), 13 while in ACS we found a reduction in pro-apoptotic proteins (e.g. Fas, Bim, and Bax). 14 Other characteristics of CD28 null T cells have been described elsewhere. The mechanisms involved in CD28 null T-cell expansion in atherosclerosis and inflammatory disorders remain poorly understood. It has been suggested that CD28 downregulation is antigen-driven. 17 Several exogenous and endogenous antigens have been proposed including cytomegalovirus and heat shock proteins (HSPs).
22,23
Strikingly, CD28 null T cells that react to oxidized LDL (ox-LDL), one of the antigens frequently implicated in atherosclerosis, have not been described. 23 An alternative hypothesis implicates inflammatory cytokines in CD28 null T-cell expansion. CD28 + T-cell clones from RA patients downregulated CD28 transcription following TNF-a treatment in vitro. 24 Conversely, infliximab triggered CD28 re-expression in cells from patients with RA or unstable angina (UA) in vitro; 25, 26 however, a different study found that etanercept and infliximab did not affect the percentage of circulating CD28 null T cells in RA patients. 27 Another mechanism that may underlie CD28 null T-cell expansion is resistance to apoptosis, due to defects in molecules regulating apoptosis entry. Recent studies implicate endogenous microRNAs (miRs) in the regulation of T-cell development, differentiation, and function, and on-going research is trying to harness miRs to target inflammatory responses in atherosclerosis. 50 Moreover, miRs have important roles in the pathophysiology of cardiovascular diseases. Cardiovascular patients have altered patterns of circulating miRs, and potential diagnostic and therapeutic applications are under investigation. 51 Of particular relevance to T cells is miR-29 that specifically inhibits IFN-g production from CD4 + T cells by targeting the transcription factors T-bet and Eomes. 52 MicroRNA-155 has also been implicated in the generation of Th1 cells, as T lymphocytes from miR-155
mice showed skewing towards Th2 with predominant production of IL-4 and IL-10 and deficient IFN-g secretion. 53 Interestingly, miR-155 was also implicated in Treg survival. 54 MicroRNA-146a is upregulated in ACS and promotes Th1 differentiation through T-bet induction. 55 The precise contribution of these miRs to the generation of CD28 null T lymphocytes and IFN-g production is currently unknown. A better characterization of the precise mechanisms that drive the inflammatory/cytotoxic functions and expansion of CD28 null T cells may unveil additional strategies to modulate this CD4 + T-cell subset in ACS patients.
Regulatory T cell-based therapies for atherosclerosis
Given their pivotal roles in immune homeostasis and prevention of excessive/harmful immune responses, substantial research efforts are focused on developing Treg-based therapies to reset dysfunctional immune responses in inflammatory diseases. Clinical trials
Targeting T cells to treat atherosclerosis employing Treg are on-going in solid-organ transplantation, type I diabetes, and graft vs. host disease. 56 These trials primarily use purification of naturally occurring FOXP3 + Treg from patients, followed by in vitro expansion and reinfusion. Protocols involving in vivo manipulation of Treg subsets (expansion of naturally occurring Treg or conversion of antigen-specific conventional T cells into Treg) are also explored ( Figure 1 ). Of note, adoptive transfer of Treg in animal models markedly reduced atherosclerosis, suggesting that a similar strategy may be beneficial in patients. 33 Moreover, several murine studies successfully demonstrate that in vivo induction of polyclonal or antigen-specific Treg (e.g. ox-LDL, ApoB100, and HSP60) reduced atherosclerosis development and/or progression. 57 One of the most promising antigens is apolipoprotein B100 (ApoB100), with several studies showing that ApoB100 peptide-based vaccines inhibited atherosclerosis in mice through Treg induction. 58, 59 Vaccination protocols using ApoB100 are being developed for first-in-human clinical trials.
Immunosuppressive drug treatment has been suggested to affect Treg in atherosclerotic plaques. A randomized control trial on a small group of patients with atherosclerotic carotid artery stenosis found that mycophenolate mofetil, an immunosuppressive drug used to prevent allograft rejection due to its ability to inhibit activated T-cell proliferation, caused not only a reduction in activated (CD3 + CD69 + ) T cells, but also an increase in CD3 + Foxp3 + in carotid atherosclerotic lesions. 60 The safety and efficacy of Treg-based therapies in human atherosclerosis has not yet been investigated and important issues remain to be addressed for optimal design of protocols utilizing adoptive transfer of Treg or vaccines that induce Treg in vivo. An important challenge for Treg-based immunotherapy remains the stability of Treg during in vitro manipulation and following reinfusion in patients with on-going inflammation. Several studies suggest that Treg may lose FOXP3 expression during in vitro culture or following reinfusion into hosts, which associates with decreased suppression, and possibly Treg conversion into pathogenic T cells. 32 Moreover, to efficiently break the chronic inflammation cycle, Treg-based therapies may not be sufficient and may need to be combined with strategies that deplete/modulate pro-inflammatory T cells.
Future directions
On-going clinical trials testing anti-inflammatory therapies in patients with coronary atherosclerosis target inflammatory cytokines (IL-1b, IL-6, and TNF-a). 4 Although these trials will bring valuable information on the role of inflammation in atherosclerosis, it is clear that both pro-atherogenic and atheroprotective immune networks operate in this disease. Moreover, considering the complexity and heterogeneity of atherosclerosis in humans, a more targeted immune-modulatory approach, adapted to the predominant pathogenic mechanisms, may be required. Current long-term immunomodulation protocols harbour considerable side effects (infections, immunosuppression, and malignancy). Therefore, careful assessment of benefit/risk profile and development of safer, more targeted immunomodulation therapies are required in atherosclerosis, wherein the inflammatory process is often more discreet than in other chronic inflammatory disorders. 
